Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TQC3302
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
TQC3302 is an experimental inhalation spray being developed by Chia Tai Tianqing Pharmaceutical for the treatment of chronic obstructive pulmonary disease (COPD). It is described as a targeted inhibitor intended for pulmonary delivery. In Phase I clinical studies conducted in China, the drug is being evaluated for its safety, tolerability, and pharmacokinetic profile in healthy adult subjects, both as a monotherapy and in sequential administration with standard COPD treatments such as long-acting muscarinic antagonists (LAMA), long-acting beta-agonists (LABA), and inhaled corticosteroids (ICS).
- Other names
- TQC3302 inhalation sprayTQC-3302 inhalation sprayTQC 3302 inhalation spray
Beyond the preview
Go deeper on TQC3302.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TQC3302.